Literature DB >> 15797753

Cardiac transplantation in patients with iron overload cardiomyopathy.

Amitra E Caines1, Jacques Kpodonu, Malek G Massad, Rabih Chaer, Alexander Evans, John C Lee, Alexander S Geha.   

Abstract

A review of the published world experience with heart transplantation for iron overload cardiomyopathy (IOC) between 1967 and 2003 as well as review of unpublished cases from the database of the United Network for Organ Sharing since 1992, identified a total of 16 patients (14 men and 2 women). Mean age was 31 years (range, 14-63 years). IOC etiology was hemochromatosis in 11 patients (69%), thalassemia major in 4 (25%), and Diamond-Blackfan anemia in 1 (6%). The 30-day mortality was 12%. Three patients (19%) died within 1 year of the transplant, all of infectious complications. An additional patient died at 7.14 years (unknown cause). The actuarial Kaplan-Meier 1-, 3-, and 5-year survival rates were 81% for all 3 time intervals. The actuarial 10-year survival was 41%.

Entities:  

Mesh:

Year:  2005        PMID: 15797753     DOI: 10.1016/j.healun.2004.02.009

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy.

Authors:  A W Demant; A Schmiedel; R Büttner; T Lewalter; C Reichel
Journal:  Clin Res Cardiol       Date:  2007-08-20       Impact factor: 5.460

Review 2.  Transplantation in patients with iron overload: is there a place for magnetic resonance imaging? : Transplantation in iron overload.

Authors:  Sophie Mavrogeni; Genovefa Kolovou; Boris Bigalke; Angelos Rigopoulos; Michel Noutsias; Stamatis Adamopoulos
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 3.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Iron overload cardiomyopathy: better understanding of an increasing disorder.

Authors:  Pradeep Gujja; Douglas R Rosing; Dorothy J Tripodi; Yukitaka Shizukuda
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

5.  Phlebotomies as a treatment of serious heart failure due to haemochromatosis: a case report.

Authors:  R V H P Huijskes; K Hoogenberg; A C P Wiesfeld; M E J Pijl; I C van Gelder
Journal:  Neth Heart J       Date:  2009-11       Impact factor: 2.380

Review 6.  Infiltrative Cardiomyopathies.

Authors:  David Bejar; Paolo C Colombo; Farhana Latif; Melana Yuzefpolskaya
Journal:  Clin Med Insights Cardiol       Date:  2015-07-08

Review 7.  Overview of Restrictive Cardiomyopathies.

Authors:  Smitha Narayana Gowda; Hyeon-Ju Ali; Imad Hussain
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

8.  Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo.

Authors:  Kristine V Brautaset Englund; Charlotte M Østby; Kaspar Broch; Thor Ueland; Pål Aukrust; Einar Gude; Arne K Andreassen; Lars Gullestad
Journal:  Clin Transplant       Date:  2022-06-01       Impact factor: 3.456

9.  Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.

Authors:  Shamil D Cooray; Neel M Heerasing; Laura A Selkrig; V Nathan Subramaniam; P Shane Hamblin; Cameron J McDonald; Catriona A McLean; Elissa McNamara; Angeline S Leet; Stuart K Roberts
Journal:  J Med Case Rep       Date:  2018-01-26

10.  Management of cardiac hemochromatosis.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.